Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Presbyopia

Therapeutic area intelligence for Presbyopia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Ocuphire Pharma →

Assets

Recent signals(2)

ClinicalJuly 19, 2026

Study Compares Laser Blended Vision and Monovision LASIK for Presbyopia

A clinical trial is underway to compare laser blended vision (LBV) with conventional monovision LASIK for treating presbyopia.

ClinicalJuly 18, 2026

Ocuphire Pharma initiates trial for Nyxol in presbyopia with adjunctive pilocarpine

A clinical trial is underway to assess the safety and efficacy of Nyxol eye drops, both as a standalone treatment and in combination with low-dose pilocarpine, for improving near visual acuity in presbyopia patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.